Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

20 Sep 2005 09:13

ReNeuron Group plc20 September 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS Please note this replaces the announcement made 13:01, 16 September 2005 underRNS number 3827R. The only material change to the body of the text being thedeletion of the holding of Mr M. Hunt, which had been appropriately disclosed inRNS announcement 3838R. This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transactionrelating to the shares or debentures of the issuer should complete boxes 1 to16, 23 and 24. (2) An issuer making a notification in respect of a derivative relatingto the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23and 24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financialinstrument relating to the shares of the issuer (other than a debenture) shouldcomplete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or RENEURON GROUP PLC (ii) DR3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial 4. State whether notification relates to a person responsibilities/director connected with a person discharging managerial responsibilities/director named in 3 and PAUL HARPER identify the connected person TREVOR JONES 5. Indicate whether the notification is in 6. Description of shares (including class), respect of a holding of the person referred debentures or derivatives or financial to in 3 or 4 above or in respect of a instruments relating to shares non-beneficial interest3 7. Name of registered shareholders(s) and, if 8. State the nature of the transaction more than one, the number of shares held by each of them 9. Number of shares, debentures or financial 10. Percentage of issued class acquired (treasury instruments relating to shares acquired shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial 12. Percentage of issued class disposed (treasury instruments relating to shares disposed shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and 16. Date issuer informed of transaction total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised DURING THE 10 YEAR PERIOD FOLLOWING GRANT, SUBJECT TO VESTING AND PERFORMANCE CONDIDTIONS 6 SEPTEMBER 2005 (FOR EACH) 19. Total amount paid (if any) for grant of the 20. Description of shares or debentures involved option (class and number) PAUL HARPER 50,000 ORDINARY SHARES TREVOR JONES 50,000 ORDINARY SHARES NIL 21. Exercise price (if fixed at time of grant) 22. Total number of shares or debentures over or indication that price is to be fixed at the time which options held following notification of exercise PAUL HARPER: 50,000 OPTIONS TREVOR JONES: 150,000 OPTIONS £0.25 PER SHARE 23. Any additional information 24. Name of contact and telephone number for queries TIM MICKLEY, COLLINS STEWART 020 7523 8000 NON EXECUTIVE FLOTATION OPTIONS GRANTED UNDER THE COMPANY'S NON EXECUTIVE SHARE MICHAEL HUNT RENEURON 01483 302 560 OPTION SCHEME Name and signature of duly authorised officer of issuer responsible for making notification MICHAEL HUNT CHIEF EXECUTIVE OFFICER-______________________________________ Date of notification 16/9/05 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Jan 20127:00 amRNSWebcast and content of Stem Cell Technical Seminar
11th Jan 201212:20 pmRNSChange of Adviser and Broker
11th Jan 20127:00 amRNSStability of lead stem cell line
9th Jan 201210:00 amRNSReNeuron to present at US healthcare conference
9th Jan 20127:00 amRNSNotification of Stem Cell Technical Seminar
3rd Jan 20127:00 amRNSData confirms pre-clinical efficacy of ReN001
19th Dec 20114:41 pmRNSSecond Price Monitoring Extn
19th Dec 20114:35 pmRNSPrice Monitoring Extension
6th Dec 201110:00 amRNSWelcomes UK Government Life Sciences Strategy
30th Nov 20114:35 pmRNSPrice Monitoring Extension
28th Nov 20117:00 amRNSStroke Update
28th Nov 20117:00 amRNSInterim Results
9th Nov 20117:00 amRNSStroke clinical trial update & notice of results
3rd Nov 20112:54 pmRNSNotification of Major Interest in Shares
1st Nov 20112:13 pmRNSNotification of Interest in Shares
31st Oct 201110:42 amRNSNotification of Major Interest in Shares
22nd Sep 201112:53 pmRNSDirectors' Interest in Shares and Share Options
22nd Sep 201112:48 pmRNSDirectors' Interest in Shares
15th Sep 201110:45 amRNSResults of 2011 Annual General Meeting
15th Sep 20117:00 amRNSAGM Trading Update
1st Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20117:00 amRNSReNeuron receives DSMB clearance
29th Jul 20113:24 pmRNSAnnual Report and Accounts and Notice of AGM
20th Jul 20117:00 amRNSBoard Appointments
5th Jul 20117:00 amRNSContract with Angel Biotechnology Holdings plc
5th Jul 20117:00 amRNSAngel signs new contract with ReNeuron
30th Jun 20117:00 amRNSPreliminary Results
24th Jun 20112:56 pmRNSReNeuron launches new website
16th Jun 20117:00 amRNSLicense agreement with US eye research institute
1st Jun 20119:43 amRNSBlock Listing Six Monthly Review
27th May 20117:00 amRNSNotice of Results and Stroke Clinical Trial Update
28th Apr 201112:22 pmRNSEU legal opinion
8th Apr 20117:00 amRNSManufacturing Agreement
28th Jan 20117:00 amRNSSettlement with Neuralstem, Inc
10th Jan 20112:18 pmRNSTR-1 Notification of major interest in shares
10th Jan 20117:00 amRNSTR-1 Notification of major interest in shares
7th Jan 20117:00 amRNSTR-1: Notification of major interest in shares
4th Jan 20117:00 amRNSMajor Interest in Shares
29th Dec 201011:34 amRNSRESULT OF GENERAL MEETING & THIRD ADMISSION
21st Dec 20107:00 amRNSUpdate on clinical trial
20th Dec 20108:01 amRNSSECOND ADMISSION
17th Dec 20108:01 amRNSFIRST ADMISSION
13th Dec 20107:01 amRNSInterim Results
13th Dec 20107:00 amRNS£10 million Fundraising
1st Dec 20107:00 amRNSBlock Listing Six Monthly Review
17th Nov 20104:41 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
17th Nov 20107:00 amRNSProgress update on ReN009
16th Nov 20107:00 amRNSFirst Patient Treated with ReN001
27th Oct 20107:00 amRNSReNeuron at stem cell and neuroscience conferences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.